Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-A3334 +/- Anlotinib in Advanced Non-Small Cell Lung Cancer
NCT06507891Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tq-a3334 in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2020; status: terminated.
02
Drugs
tq-a3334
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06507891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06507891.